Alnylam Pharmaceuticals, Inc. (ALNY) vs argenex SE (ARGX)

Alnylam Pharmaceuticals, Inc. and argenex SE are both Biotechnology companies. argenex SE is the larger, with a market value of $60.2B against $31.2B — 1.9× the size. argenex SE trades at the lower P/E: 34.6× against 43.6×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 70.6%. argenex SE has the higher net margin (32.2% vs 16.1%) and the higher return on invested capital (20.7% vs 0.00%). Across the 21 metrics below, argenex SE leads on 12 and Alnylam Pharmaceuticals, Inc. on 9.

Valuation

Metric ALNY ARGX Biotechnology median
P/E 43.62 34.61 7.88
P/S 7.12 11.22 11.47
P/B 25.25 7.10 2.52
Price to free cash flow 41.71 43.37 21.16
EV/EBITDA 30.25 35.09 0.74
EV/Sales 6.64 10.55 10.73
Earnings yield 2.29% 2.89% (28.84%)
Free cash flow yield 2.40% 2.31% (23.03%)

Profitability

Metric ALNY ARGX Biotechnology median
Gross margin 79.65% 90.15% 65.16%
Operating margin 20.81% 30.06% 0.00%
Net margin 16.13% 32.20% 0.00%
Free cash flow margin 17.07% 25.87% 0.00%
Return on equity 96.55% 27.07% (57.72%)
Return on assets 15.30% 19.95% (49.22%)
Return on invested capital 0.00% 20.71% 0.00%

Growth

Metric ALNY ARGX Biotechnology median
Revenue growth (TTM) 95.14% 70.58% 5.64%
EPS growth (last fiscal year) 206.88% 53.13% —
Revenue growth, 5-year CAGR 49.77% 130.77% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALNY ARGX Biotechnology median
Debt to equity 0.75 0.00 0.00
Current ratio 3.05 5.12 4.73
Net debt to EBITDA (3.41) (3.23) 0.96

Dividend

Metric ALNY ARGX Biotechnology median
Dividend yield 2.52% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALNY ARGX Biotechnology median
Market cap 31.16b 60.20b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack